GDF11 and aging biology - controversies resolved and pending
The Journal of Cardiovascular Aging · 2023-10-19 · 3 (4)
DOI: 10.20517/jca.2023.23 ↗At a glance
Journal article in The Journal of Cardiovascular Aging, published online on 2023-10-19. Written by Laura Ben Driss and 7 co-authors. Institution: Department of Stem Cell and Regenerative Biology and the Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA. Cited 12 times so far (Crossref); 106 references. The full text is freely available in PubMed Central. Funded by: NIGMS NIH HHS, NIA NIH HHS, NHLBI NIH HHS.
Abstract (original language)
Since the exogenous administration of GDF11, a TGF-ß superfamily member, was reported to have beneficial effects in some models of human disease, there have been many research studies in GDF11 biology. However, many studies have now confirmed that exogenous administration of GDF11 can improve physiology in disease models, including cardiac fibrosis, experimental stroke, and disordered metabolism. GDF11 is similar to GDF8 (also called Myostatin), differing only by 11 amino acids in their mature signaling domains. These two proteins are now known to be biochemically different both in vitro and in vivo . GDF11 is much more potent than GDF8 and induces more strongly SMAD2 phosphorylation in the myocardium compared to GDF8. GDF8 and GDF11 prodomain are only 52% identical and are cleaved by different Tolloid proteases to liberate the mature signaling domain from inhibition of the prodomain. Here, we review the state of GDF11 biology, highlighting both resolved and remaining controversies.
Subjects
Author keywords
Authors and institutions
- Department of Stem Cell and Regenerative Biology and the Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.
- Department of Molecular and Cellular Biosciences, University of Cincinnati, Cincinnati, OH 45267, USA.
- Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH 45267, USA.
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
- Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Joslin Diabetes Center, Boston, MA 02115, USA.
- Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Funding
- NIGMS NIH HHS
- NIA NIH HHS
- NHLBI NIH HHS
Cite
APA
Driss, L. B., Lian, J., Walker, R. G., Howard, J. A., Thompson, T. B., Rubin, L. L., Wagers, A. J., & Lee, R. T. (2023). GDF11 and aging biology - controversies resolved and pending. The Journal of Cardiovascular Aging, 3(4). https://doi.org/10.20517/jca.2023.23
Vancouver
Driss LB, Lian J, Walker RG, Howard JA, Thompson TB, Rubin LL, et al. GDF11 and aging biology - controversies resolved and pending. The Journal of Cardiovascular Aging. 2023;3(4). doi:10.20517/jca.2023.23
BibTeX
@article{Driss2023,
author = {Driss, Laura Ben and Lian, John and Walker, Ryan G and Howard, James A and Thompson, Thomas B and Rubin, Lee L and Wagers, Amy J and Lee, Richard T},
title = {GDF11 and aging biology - controversies resolved and pending},
journal = {The Journal of Cardiovascular Aging},
year = {2023},
volume = {3},
number = {4},
doi = {10.20517/jca.2023.23}
}
EUVIMED